Все публикации

1:00:32

PGx Webinar: Guideline-Driven Pharmacogenomic Testing and the Trajectory of Utilization

0:33:10

Agena Bioscience AMP 2024 Workshop Oncology

0:32:40

Agena Bioscience AMP 2024 Workshop PGx

1:00:20

Panel Talk: Standardizing Pharmacogenomics Laboratory Processes and Reporting

0:52:58

Advocating for DPYD Testing to Advance Patient Safety Based on Insights from Clinical Evidence

0:38:46

Rethinking Solid Tumor Profiling: How Complementary Technologies Allow Better Treatment Decisions

1:00:41

Webinar: PGx Testing Developments and Future Directions

0:51:59

Webinar: Unlocking Precision Medicine - Implementing a Novel PGx Prescribing Program

1:04:42

Webinar: PGx-Guided Pharmacotherapy: Recent Developments & Implementation in Clinical Practice

1:01:08

Webinar: Performing Population-based Newborn Screening for Cystic Fibrosis in the State of Illinois

1:02:05

Webinar: Recent Developments in PGx – Predictive Biomarker Identification and Relevance

0:36:05

Advancement of Pharmacogenomic (PGx) Testing: Development of Evidence-based Guidelines

0:22:36

Webinar: Authenticating Laboratory Results – Molecular Sample Tracking for NGS Laboratories

0:56:48

Webinar: Detection of therapeutically targetable mutations in NSCLC

1:00:10

Webinar: The Promise of Liquid Biopsy for Individualizing Cancer Care

0:18:32

Detection & Discrimination of SARS-CoV-2 Variants of Concern - An Alternative Approach to NGS

0:58:29

Webinar: Responding to Emerging SARS CoV 2 Variants

0:02:10

Hybrid Alleles: Why It's Important to Detect Them & How Agena Does it Better

0:57:57

Webinar: Responding to the COVID-19 Pandemic - Clinical Laboratories Perspectives

0:43:43

Webinar: Going beyond EGFR: Evaluating technologies for molecular genetic testing in NSCLC

0:07:08

MassARRAY® System by Agena Bioscience – 2020

0:57:57

Webinar: Targeted Detection of MET and NTRK Oncogenic Variants in Routine Molecular Analysis

1:03:14

AMP 2019 PGx Workshop: The Prevalence and Impact of CYP2D6 Hybrid Alleles

0:56:45

Low Cost, High Sensitivity: The Advantages of MALDI-TOF for Liquid Biopsy and Solid Tumor Profiling